Prevalence of human papillomavirus genotypes in high‐grade cervical precancer and invasive cervical cancer from cancer registries before and after vaccine introduction in the United States

Cancer ◽  
2021 ◽  
Author(s):  
Jacqueline M. Mix ◽  
Mona Saraiya ◽  
Trevor D. Thompson ◽  
Troy D. Querec ◽  
April Greek ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Invasive Cervical Cancer ◽  
Cancer Registries ◽  
The United States ◽  
High Grade ◽  
Vaccine Introduction ◽  
Before And After ◽  
Cervical Precancer

Utilization of Diagnostic Studies in the Pretreatment Evaluation of Invasive Cervical Cancer in the United States: Results of Intergroup Protocol ACRIN 6651/GOG 183

2005 ◽  
Vol 23 (30) ◽  
pp. 7454-7459 ◽  
Author(s):  
Marco A. Amendola ◽  
Hedvig Hricak ◽  
Donald G. Mitchell ◽  
Bradley Snyder ◽  
Dennis S. Chi ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Data Analysis ◽  
Diagnostic Tests ◽  
Gynecologic Oncology ◽  
Invasive Cervical Cancer ◽  
The United States ◽  
Patterns Of Care ◽  
Clinical Staging ◽  
Gynecologic Oncology Group

Purpose To review the current utilization of diagnostic tests prescribed by the International Federation of Gynecology and Obstetrics (FIGO) clinical staging guidelines in the pretreatment work-up of invasive cervical cancer, and to compare the data with those of previous patterns of care studies. Patients and Methods This interdisciplinary American College of Radiology Imaging Network/Gynecologic Oncology Group prospective clinical trial was conducted between March 1, 2000, and November 11, 2002. Twenty-five participating institutions, all from the United States, enrolled a total of 208 patients. Only patients scheduled for surgery with biopsy-confirmed cervical cancer of clinical FIGO stage IB or higher were eligible. The patterns of care data analysis was based on 197 patients who met all inclusion criteria. The conventional FIGO-recommended tests used for pre-enrollment FIGO clinical stage classification were at the discretion of the treating physician; overall frequency of use was tabulated for each test. Results Use of cystoscopy (8.1%) and sigmoidoscopy or proctoscopy (8.6%) was significantly lower than in 1988 to 1989 (P < .0001 in each instance). Intravenous urography was used in only 1% of patients as compared with 42% in 1988 to 1989 and 91% in 1983. No patient included in the data analysis had barium enema or lymphangiography. Only 26.9% of patients had examination under anesthesia for FIGO clinical staging. Conclusion There is a large discrepancy between the diagnostic tests recommended by FIGO and the actual tests used for cervical cancer staging, suggesting a need to reassess the relevance of the FIGO guidelines to current clinical practice in the United States.

scholarly journals Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009–2012

2017 ◽  
Vol 103 ◽  
pp. 60-65 ◽  
Author(s):  
Meg Watson ◽  
Ashwini Soman ◽  
Elaine W. Flagg ◽  
Elizabeth Unger ◽  
Dennis Deapen ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Cancer Registries ◽  
Population Based ◽  
High Grade ◽  
Cin Iii ◽  
Cancer Precursors

Incidence and Survival Rates of Gynecological Malignancies in The United States Before and After the HPV Vaccine

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 22-22
Author(s):  
N Talibova ◽  
A Sohaib ◽  
M Gouda ◽  
M Gunaldi
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Statistical Analysis ◽  
Hpv Vaccine ◽  
Survival Rates ◽  
The United States ◽  
Mortality Rates ◽  
Gynecological Malignancy ◽  
Gynecological Malignancies ◽  
Before And After

Intoduction: Gynecological malignancies are one of the most common cancers in women and have high mortality rates in the United States. In this study, we aimed to analyze the incidence and mortality rates of gynecological malignancies in 2011-2015 and compare these data with the corresponding parameters of 2001-2005. We chose these intervals of years for contrasting, as HPV vaccines have been actively used since 2006. HPV vaccine is known to prevent cervical cancer but has unknown impact on other gynecological malignancies. The aim of the is study is to check if incidence and survival of gynecological malignancies has changed before and after application of HPV vaccine Material and Methods: The Surveillance, Epidemiology and End Results (SEER) cancer registry 2005-2011 and 2011-2015 database was investigated and patients with gynecological malignancy were identified. Data were obtained using SEER*Stat version 8.3.5. A statistical analysis on the incidence rate and mortality rate was performed. Data were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25. Results: Overall 125,357 cases with a gynecological malignancy were identified in 2011-2015 in comparison with 102,534 cases in the period of 2001-2005. The incidence of cervical cancer decreased in the period of 2011-2015 compared with the period from 2001 to 2005 (median incidence rates 3.9 and 4.3 per 100.000 persons, respectively, p < 0.05), while incidence of uterine (15.3 and 12.0 per 100.000 persons persons, respectively) and vulvar (1.55 and 1.86 per 100.000 persons, respectively) has increased ( p < 0.05). There was no change in the incidence rate of ovarian cancer (7.28 and 7.19 per 100.000 persons). Survival rates for cervix, uterine, ovarian and vulva cancer have increased. However, zero time error couldn’t be avoided in statistical analysis. Conclusion: As a result of widespread screening with Pap smear test and availability of human papilloma virus vaccine the incidence of cervix cancer has declined. Increase in vulvar and uterine cancer incidence may be attributed to lack of effective screening program for early detection of these type of cancers and most probably HPV vaccine has no effect on their incidence. Survival of gynecological malignancies has increased over years which may be explained by better treatment options or earlier detection.

Cervical Dysplasia and Human Papillomavirus

2018 ◽  
Author(s):  
Melissa K Frey ◽  
Cathleen E Matrai
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Invasive Cervical Cancer ◽  
Cervical Dysplasia ◽  
The United States ◽  
Hpv Infection ◽  
Low Grade ◽  
Human Papillomavirus Vaccine ◽  
Papanicolaou Test ◽  
Screening Programs

Human papillomavirus (HPV) affects the majority of sexually active individuals and accounts for approximately 5% of human cancers and nearly 100% of cervical cancer cases. The progression from persistent HPV infection to invasive cervical cancer takes at least 10 years and is preceded by epithelial dysplastic changes. Cytologic screening programs, which rely on disease detection during this precancerous interval, have successfully decreased the incidence of cervical cancer. The HPV vaccine, approved since 2006, effectively decreases cervical disease but remains underused in the United States and abroad, with the incidence of HPV-related cancers still on the rise. In this review, we discuss the epidemiology and molecular pathogenesis of HPV infections and cervical cancer development, cervical cancer screening and screening terminology, management of abnormal screening results, and HPV vaccination.   This review contains 4 figures, 8 tables and 49 references Key words: atypical squamous cells of undetermined significance, cervical cancer, cervical intraepithelial neoplasia, colposcopy, high-grade cervical dysplasia, human papillomavirus, human papillomavirus vaccine, low-grade cervical dysplasia, Papanicolaou test, papillomaviruses  

Sign in / Sign up

Export Citation Format

Share Document